Protocol

Yeast Systems Biology

Volume 759 of the series Methods in Molecular Biology pp 239-269

Date:

The Automated Cell: Compound and Environment Screening System (ACCESS) for Chemogenomic Screening

  • Michael ProctorAffiliated withStanford Genome Technology CenterDepartment of Biochemistry, Stanford University
  • , Malene L. UrbanusAffiliated withBanting and Best Department of Medical Research, University of TorontoDonnelly Centre for Cellular and Biomolecular Research, University of Toronto
  • , Eula L. FungAffiliated withStanford Genome Technology Center
  • , Daniel F. JaramilloAffiliated withStanford Genome Technology Center
  • , Ronald W. DavisAffiliated withStanford Genome Technology CenterDepartment of Biochemistry, Stanford UniversityDepartment of Genetics, Stanford University
  • , Corey NislowAffiliated withBanting and Best Department of Medical Research, University of TorontoDonnelly Centre for Cellular and Biomolecular Research, University of TorontoDepartment of Molecular Genetics, University of Toronto
  • , Guri GiaeverAffiliated withDonnelly Centre for Cellular and Biomolecular Research, University of TorontoDepartment of Molecular Genetics, University of TorontoDepartment of Pharmaceutical Sciences, University of Toronto Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The automated cell, compound and environment screening system (ACCESS) was developed as an automated platform for chemogenomic research. In the yeast Saccharomyces cerevisiae, a number of genomic screens rely on the modulation of gene dose to determine the mode of action of bioactive compounds or the effects of environmental/compound perturbations. These and other phenotypic experiments have been shown to benefit from high-resolution growth curves and a highly automated controlled environment system that enables a wide range of multi-well assays that can be run over many days without any manual intervention. Furthermore, precise control of drug dosing, timing of drug exposure, and precise timing of cell harvesting at specific generation times are important for optimal results. Some of these benefits include the ability to derive fine distinctions between growth rates of mutant strains (1) and the discovery of novel compounds and drug targets (2). The automation has also enabled large-scale screening projects with over 100,000 unique compounds screened to date including a thousand genome-wide screens (3). The ACCESS system also has a diverse set of software tools to enable users to set up, run, annotate, and evaluate complex screens with minimal training.

Key words

Robotics phenotypic screening genome-wide screening yeast bacteria drug discovery